Analysts are estimating that Ultragenyx Pharmaceutical will report an earnings per share (EPS) of $-1.43.
Anticipation surrounds Ultragenyx Pharmaceutical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings History Snapshot
In the previous earnings release, the company beat EPS by $0.20, leading to a 14.31% increase in the share price the following trading session.
Ultragenyx Pharmaceutical Share Price Analysis
Shares of Ultragenyx Pharmaceutical were trading at $50.99 as of November 01. Over the last 52-week period, shares are up 34.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Insights Shared by Analysts on Ultragenyx Pharmaceutical
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ultragenyx Pharmaceutical.
The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.
Understanding Analyst Ratings Among Peers
The below comparison of the analyst ratings ...
